On July 13, 2016 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, reported that it has settled its ANDA patent litigation relating to FOLOTYN (Press release, Spectrum Pharmaceuticals, JUL 13, 2016, View Source [SID:1234513855]). Schedule your 30 min Free 1stOncology Demo! As a result of the settlement with the last remaining ANDA filer, Fresenius Kabi USA, LLC, and the previously reported settlements with Teva Pharmaceuticals USA, Inc., Dr. Reddy’s Laboratories, Ltd. & Dr. Reddy’s Laboratories, Inc. and Sandoz Inc., absent certain circumstances, generic versions of FOLOTYN will not be permitted to be marketed in the United States until November 15, 2022. The Company will submit the settlement agreement to the Federal Trade Commission and the Department of Justice. Details of the settlement are confidential.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!